ICIs for HCC: Q&A 1

CME

Immunotherapy for Advanced HCC: Experts Answer Clinician Questions

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Released: December 10, 2020

Expiration: December 09, 2021

Lipika Goyal
Lipika Goyal, MD, MPhil
Amit G. Singal
Amit G. Singal, MD, MS

Activity

Progress
1
Course Completed

In this episode, Amit G. Singal, MD, MS, and Lipika Goyal, MD, answer clinician questions on current best practices and emerging applications  with immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma, with topics including:

  • Optimal use of the newly approved immune checkpoint inhibitor/VEGF inhibitor combination of atezolizumab plus bevacizumab
  • Use of immune checkpoint inhibitor therapy in patients with Child-Pugh B liver function
  • Use of biomarkers to inform treatment for patients with advanced HCC